CTOs on the Move

BridgeHealth

www.bridgehealth.com

 
BridgeHealth connects people with the nation`s best surgical care for a better experience, better outcomes, and better value. We offer a value-based approach to surgical care for self-insured plan sponsors and their members, saving them an average of 30% to 50% on procedures compared with PPO rates. BridgeHealth`s nationwide Centers of Excellence focus on quality outcomes and provide pre-negotiated bundled case rates for a broad scope of surgical procedures, including musculoskeletal, neurological, general surgery, cardiac, bariatric, and women`s health. BridgeHealth contracts with hospital providers who rank in the top quartile for their clinical specialty, based on outcomes and other objective ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Kris Jamsa
Chief Technology Officer Profile

Funding

BridgeHealth raised $40M on 10/22/2020

Similar Companies

SAINT MARYS REGIONAL MEDICAL CENTER

SAINT MARYS REGIONAL MEDICAL CENTER is a Lewiston, ME-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Angela Hospice

Angela Hospice is a Livonia, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

WELLTODO

Search wellness jobs online and find a career in health, fitness and wellbeing. Discover incredible companies hiring now, tips to get the job, and support from industry experts...

Vet XPS

Vet XPS is a company that provides veterinary medical services and products. They are based in Charlotte, North Carolina and follow FDA guidelines.

Xenon Pharmateuticals

Xenon Pharmaceuticals (NASDAQ:XENE) – a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, U.S.A. – is committed to delivering innovative medicines to provide a brighter future for patients suffering from neurological disorders. At Xenon, we are advancing an exciting pipeline of neurology-focused therapies, with a particular emphasis on novel treatments for both adult and pediatric patients with epilepsy. XEN496 is currently being evaluated in the Phase 3 “EPIK” clinical trial in young patients with KCNQ2-DEE, a rare and severe form of childhood epilepsy. Late-stage development plans are also underway for our XEN1101 program, building upon the compelling data from the Phase 2b “X-TOLE” study in adult patients with focal epilepsy. We are also proud of the leading-edge science coming out of our discovery labs, with many early-stage research programs underway. In addition to Xenon`s proprietary programs, we have ongoing collaborations with our valued pharmaceutical partners. With a healthy balance sheet to support our growth plans, we continue to build a fully-integrated, premier neuroscience company with strong discovery, development, and commercial operations. Our employees are smart, passionate, dedicated, and driven by their incredibly important work to discover, develop, and deliver new medicines for patients in need. Building and maintaining a respectful, collaborative, inclusive, and productive culture is a priority for us. We are looking for great people who thrive in a fast-paced, dynamic work environment to join our team during this transformative time for Xenon.